RE: scenario15 Jul 2021 11:05
CDX Antibody
The Company announced in January 2021 that work with GlobalCo has concluded under the CDX antibody development agreement. The result was the selection of a clone of the antibody that is ready for IND-enabling studies, the key step toward clinical trials. The Company recently received notice that GlobalCo will not in-license the CDX antibody at this juncture, and accordingly gave notice to GlobalCo of its intention to exercise its own option to license GlobalCo's contributions on an exclusive, worldwide basis. As at the date of this document, the Company and GlobalCo are engaged actively in discussions regarding its future development and their respective intellectual property embodied in the final selected clone.
No more options from GB and they simple go away . Let Hemo have owe CDX and must payback some money.
Who say the deal done? It have done long time ago and now forget it . One day CDX will bring back value but not now.